The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.

Explanation of how the number of participants for analysis was determined.
Includes whether analysis was per protocol, intention to treat, or another method.
Also provides relevant details such as imputation technique, as appropriate.

Treated Set, includes all patients that were randomized and were documented to have received at least one dose of investigational treatment

Explanation of how the number of participants for analysis was determined.
Includes whether analysis was per protocol, intention to treat, or another method.
Also provides relevant details such as imputation technique, as appropriate.

Treated Set, includes all patients that were randomized and were documented to have received at least one dose of investigational treatment

Reporting Groups

Description

Tipranavir With Ritonavir (TPV/r) 500/200 mg Once Daily

Tipranavir 500 mg boosted with ritonavir 200 mg given once daily

Tipranavir With Ritonavir (TPV/r) 250/100 mg Twice Daily

Tipranavir 250 mg boosted with ritonavir 100 mg given twice daily

Tipranavir With Ritonavir (TPV/r) 500/100 mg Twice Daily

Tipranavir 500 mg boosted with ritonavir 100 mg given twice daily

Measured Values

Tipranavir With Ritonavir (TPV/r) 500/200 mg Once Daily

Tipranavir With Ritonavir (TPV/r) 250/100 mg Twice Daily

Tipranavir With Ritonavir (TPV/r) 500/100 mg Twice Daily

Participants Analyzed [Units: Participants]

30

25

24

AUC 24 of Ritonavir for QD and AUC 12 of Ritonavir for BID [Units: h*uM]Geometric Mean (Geometric Coefficient of Variation)

5.05
(44.0%)

2.25
(47.0%)

1.74
(48.9%)

No statistical analysis provided for AUC 24 of Ritonavir for QD and AUC 12 of Ritonavir for BID

11. Secondary:

Cp 24 h of Ritonavir for QD and CP 12 h of Ritonavir for BID [ Time Frame: Final (Day 13 for QD, Day 14 for BID) ]